People Are Sharing The Modern Addictions Nobody Really Thinks About, And Yes, Dopamine Is On This List
1."Validation addiction, aka the compulsive need for approval, praise, or recognition from others."
—u/RevealIntelligent737
2."Nasal spray. This one is kind of obscure, but the thought of having a stuffy nose and needing more and more and more of that stuff is kind of scary."
—u/TazzzTM
"I literally cut myself off 10 years ago because it was causing me problems."
—bobbutson
"This happened to me in fifth grade! It was so severe that I needed to use it at least once an hour, or my nose was completely blocked up. The addiction lasted weeks. I would bring it to school and sneak huffs of it from my backpack during class, pretending I was rummaging for something."
—u/iamnotahermitcrab
3."Habits that put us into the same patterns we're already familiar with. For example, let's say someone was previously abused and has low self-esteem, so they now gravitate toward people who mistreat them, etc."
—u/crypticcryptidscrypt
4."Food."
—u/LivingSalt9816
"This doesn't get talked about enough. Someone can truly quit any of these other addictions. You cannot quit eating. And even if we could, eating is the center of most cultures, communities, and fellowship."
—u/GingerrGina
5."Shopping."
—u/blissfulheadgames
6."Victim mindset."
—u/tokenasian99
Related: 23 Cute, Happy, And Wholesome Posts I Saw On The Internet This Week That You Absolutely Need To See
7."Gambling is often overlooked. It's also not just lotto tickets and bingo. Casino apps, sports betting, online gaming 'mystery boxes,' and day trading are just a few examples of things that use the same mechanics."
—u/threadbarefemur
8."Dieting, eating disorders and/or disordered eating, and counting calories."
—u/Global_Concept1331
9."Social media."
—u/Goddess_alma__
"It's a bigger issue than that. Social media falls under dopamine abuse, basically. It's just a constant onslaught of the pleasure ventures in the brain these days. Companies research ways to hit those centers and use the marketing to sell it. Small things like the action of swiping or flavors in food. Salt. Porn. Video games. Social media. YouTube showing you all the things you want but can't go for. All of these things are beneficial targeted one at a time, but goddamn, it fries people's brains all at once."
—u/Klashus
Related: Holy Crap, I Can't Stop Laughing At These 28 Painfully Awkward And Embarrassing Conversations
10."Working all the time."
—u/MotherEarth1919
11."Dermatillomania, or skin-picking disorder."
—u/strangekey2
12."Dating apps. They're like a game, and the incentive for winning is your orgasm."
—u/Present-Loss5880
13."Porn."
—u/PEACH_MINAJ
14."Sleeping in all the time."
—u/Tough_Representative
"Sleeping in general. I genuinely can't stop napping during the day. It's awful."
—u/lights-camera-bees
15."Weed. While it's not an addictive substance, people definitely become emotionally dependent. One problem is that weed makes you okay with being unproductive and bored, and many people use it as a crutch."
—u/8v9
16."Phones."
—u/Then_Coyote_1244
"That's me — same with my iPad. When I iron my clothes, I put on YouTube on my iPad. Eating dinner? Netflix. Drinking a cup of tea? TikTok. Waiting on the bus? Reddit. My phone is always in my hand. I take it with me when I go to bed, when I take a shower, when I walk the dog, when I have to get something from the attic, etc. I miss growing up in the '90s and not having a phone — just being present in the moment. But somehow, I can't do it anymore."
—u/Dazzling-Yam-1151
What do you think after reading these responses? Are you recognizing some (completely normalized) patterns in your own life or others? What hidden addictions do you think are affecting people today? Share your thoughts and experiences in the comments below.
The National Alliance on Mental Illness helpline is 1-800-950-6264 (NAMI) and provides information and referral services; GoodTherapy.org is an association of mental health professionals from more than 25 countries who support efforts to reduce harm in therapy.
The National Eating Disorders Association helpline is 1-800-931-2237; for 24/7 crisis support, text 'NEDA' to 741741.
If you or someone you know is in immediate danger as a result of domestic violence, call 911. For anonymous, confidential help, you can call the 24/7 National Domestic Violence Hotline at 1-800-799-7233 (SAFE) or chat with an advocate via the website.
Also in Internet Finds: Lawyers Are Sharing Their Juiciest "Can You Believe It?!" Stories From The Courtroom, And They're As Surprising As You'd Expect
Also in Internet Finds: 51 People Who Quickly Discovered Why Their Hilariously Clueless Partner Was Single Before Meeting Them
Also in Internet Finds: People Are Sharing "The Most Believable Conspiracy Theories," And Now I'm Questioning Everything I Thought I Knew
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
1 Beaten-Down Stock That Could Soar by the End of the Year
Key Points Viking's leading weight management candidate is being investigated in two formulations. The stock could soar later this year, provided the oral version aces phase 2 studies. Viking Therapeutics is somewhat risky, but it also has significant upside potential. 10 stocks we like better than Viking Therapeutics › Some smaller drugmakers choose to develop medicines for diseases for which there are no therapeutic options. This allows them to avoid direct competition from larger pharmaceutical companies. That's not exactly the strategy Viking Therapeutics (NASDAQ: VKTX) chose. The mid-cap biotech is working on weight loss therapies, an increasingly competitive market dominated by Eli Lilly (NYSE: LLY) and Novo Nordisk, as well as numerous other well-established players in the industry seeking to enter the space. Going up against these giants is no small challenge, but Viking is, so far, holding its own. And if it can play its cards right, its stock could soar by the end of the year and go on to generate strong returns from then on out. Here's more on Viking Therapeutics. Eli Lilly's setback creates an opportunity Viking Therapeutics' shares soared last year following the release of strong phase 2 data for its subcutaneous weight management candidate, VK2735. The stock has declined significantly since that milestone, although it's not due to anything Viking did wrong. Broader market volatility, combined with long-term shareholders taking some profits, is likely responsible for the stock's 40% drop over the trailing-12-month period. VK2735 is currently in phase 3 studies, but Viking is also developing an oral version of the medicine, which is in phase 2 clinical trials. There is a race to develop a highly effective oral GLP-1 anti-obesity therapy, since the current market leaders are administered via subcutaneous injection. If Viking Therapeutics' oral candidate can impress in mid-stage studies, the stock could soar. That's especially the case since Eli Lilly's investigational oral GLP-1 medicine, orforglipron, failed to perform as well as expected in a phase 3 study in obese or overweight patients who didn't have diabetes. Orforglipron led to a mean weight loss of 12.4% in a 72-week study, which wasn't as impressive as the market wanted. This result paled in comparison to Lilly's injectable Zepbound, which led to an average weight loss of 20.2% in a phase 3 study. Viking Therapeutics' shares jumped on the pharmaceutical giant's bad news, but there's plenty of upside left if its oral weight loss candidate meets Wall Street's expectations. It's best to start small Eli Lilly is perceived as the leader in the weight management market. The company's continued dominance in this field was likely somewhat baked into investor expectations, requiring it to deliver outstanding clinical trial results to justify its share price. Viking is a much smaller drugmaker than Lilly, so the market will likely have lower expectations for its data readouts for VK2735. Viking also has several other exciting candidates. The company is working on a drug called VK2809, a potential therapy for metabolic dysfunction-associated steatohepatitis (MASH), which produced solid results in phase 2 studies. There is a vast unmet need in MASH, considering several million people have the disease, yet the U.S. Food and Drug Administration has approved just a single medication for it. Elsewhere, Viking has a next-gen anti-obesity candidate that could soon start human clinical trials. The company has a lot going on, and if VK2735-related developments remain strong through the end of the year, the stock could soar. However, Viking -- like any clinical-stage biotech company -- is a somewhat risky bet. On the one hand, it has generated strong mid-stage data for two separate medicines that address high unmet needs. Its leading candidate, VK2735, has the potential to become a blockbuster; that's impressive. Even so, the stock will plummet if VK2735 encounters clinical setbacks. So, should you buy shares? In my view, it depends on your level of risk tolerance. Risk-averse investors should look elsewhere. If you're comfortable with a bit of volatility, you should seriously consider the stock; however, it would be wise to start by initiating a small position. If the data from the ongoing phase 2 study for oral VK2735 is good, it might be worth adding even more shares thereafter. Should you buy stock in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Beaten-Down Stock That Could Soar by the End of the Year was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio
Fox News
an hour ago
- Fox News
Frustrated man says pregnant sister's food habits forced him to lock up groceries
A frustrated man turned to Reddit after his pregnant sister kept eating his food without asking, leading to an outpouring of support. In a post on the popular platform, the 30-year-old man shared that his 31-year-old sister had recently left her husband and moved in with him. "I have a small apartment, but I let her move in because she had nowhere else to go and she's six months pregnant," he wrote. "I wasn't very pleased about this situation, but she is my sis, after all." At first, things were going fine – until his food started disappearing. The man wrote that he has very specific foods for his fitness goals and that his sister has been eating these — including his expensive shakes, post-run snacks and meal preps. "I'm pretty disciplined about what I eat because I am in bulk stage and hitting the gym regularly," he wrote. "I portion things, label them and plan for the entire week. But every other day something's gone. Makes me crazy." When confronted about her eating habits, the sister responded by shrugging or blaming hormones. "I asked her to replace things she finishes or at least ask before taking something. … She refuses to do anything about it," he said. When the man resorted to buying a small mini-fridge and putting it in his bedroom, the sister accused him of "treating her like a thief." "I calmly told her I was tired of my groceries disappearing and that this was the easiest way to avoid fights," he said. "Now she's sulking and has told our parents, after her failed marriage, her brother is also alienating her." "Sibling relationships are often the hardest ones we ever deal with." The man sharing his story on Reddit also reported that his mother called him and said that "pregnancy isn't easy," especially with his sister's situation. "I don't think I'm being cruel … I just want my food to be left alone. A part of me understands she is going through trouble. But at my expense?" he concluded. Commenters almost unanimously sided with the man. "Where is she going to stay once the baby is born? You have got bigger problems than groceries, if she won't even contribute to food costs," one person observed. "Tell your mother to come get your sister, so she can be sure that your sister is being taken care of," another chimed in. "Boundaries must be put in place with no apologies." California-based relationship expert Audrey Hope told Fox News Digital the central issue of the disagreement goes far beyond food. "Sibling relationships are often the hardest ones we ever deal with," she noted. "And there [may be] a primal wound that began long ago in childhood that went unnoticed and unhealed." Hope also said that the pregnant sister "was probably pampered" as a child, leading to her entitlement as an adult. "Boundaries must be put in place with no apologies," she advised. "The sibling with the apartment needs to know that he is being mistreated, and it is time to own his self-esteem and self-love and put up strong boundaries."
